Lamy

LAMY completed the acquisition of Exousia Ai, Inc., shifting its business focus to clinical-stage biotechnology developing plant-based exosome therapies for oncology, dermatology, and anti-aging.

LAMY has undergone a change in control with Zhang Shengwu acquiring a majority stake and assuming leadership roles, effective December 6, 2024.

LAMY has dismissed Bush and Associates CPA as their independent auditor and appointed Boladale Lawal & Co, effective immediately.

Exousia Bio, Inc. (formerly LAMY) has transitioned its business focus to clinical-stage biotechnology, specifically exosome therapeutics for oncology, and reported a net loss for the nine months ended February 28, 2026.

Exousia Bio, formerly LAMY, has pivoted to a clinical-stage biotechnology focus after acquiring Exousia AI, securing a $250,000 convertible note amidst a significant net loss and going concern warning.

LAMY, a development-stage company, reported no revenue and a significant increase in net loss for the quarter ended August 31, 2025, raising substantial doubt about its ability to continue as a going concern.

LAMY, a development-stage corporation focused on financial education through video games, reports a net income of $54,895 for the nine months ended February 28, 2025, following a change in control on December 6, 2024.

LAMY reports a net income of $80,659 for the six months ended November 30, 2024, alongside a significant change in ownership and control.

LAMY Inc. reports increased revenue for the quarter ended August 31, 2024, but continues to operate at a loss with substantial doubt about its ability to continue as a going concern.

LAMY announced a change in control with Zhang Shengwu acquiring majority shares, reported net income for FY2025 despite revenue decline, and faces substantial doubt about its ability to continue as a going concern.

LAMY's annual report for fiscal year 2024 reveals the company generated its first revenue, but also highlights ongoing losses and concerns about its ability to continue as a going concern.